A case of sporadic late‐onset nemaline myopathy without monoclonal gammopathy of unknown significance/human immunodeficiency virus successfully treated with intravenous gamma globulin

2020 ◽  
Author(s):  
Ryosuke Fukazawa ◽  
Masanori Cho ◽  
Yukihiro Hidaka ◽  
Hidesato Takezawa ◽  
Masashi Ogasawara ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Monoclonal Gammopathy ◽  
Gamma Globulin ◽  
Late Onset ◽  
Nemaline Myopathy ◽  
Immunodeficiency Virus ◽  
Unknown Significance ◽  
Intravenous Gamma Globulin

scholarly journals Seronegative Myasthenia Gravis and Human Immunodeficiency Virus Infection: Response to Intravenous Gamma Globulin and Prednisone

1998 ◽  
Vol 25 (3) ◽  
pp. 254-256 ◽  
Author(s):  
James Strong ◽  
Douglas W. Zochodne
Keyword(s):  
Human Immunodeficiency Virus ◽  
Virus Infection ◽  
Human Immunodeficiency Virus Infection ◽  
Myasthenia Gravis ◽  
Gamma Globulin ◽  
Prednisone Therapy ◽  
Seronegative Myasthenia Gravis ◽  
Immunodeficiency Virus ◽  
Intravenous Gamma Globulin

ABSTRACT:Background:There are only rare reports of myasthenia gravis complicating human immunodeficiency virus infection. The role of immunomodulatory therapy is unknown.Methods:Case report and literature review.Results:The diagnosis of human immunodeficiency virus infection followed that of myasthenia gravis in a 35-year-old man. Clinical and electrophysiological features were diagnostic of generalized myasthenia gravis but two edrophonium chloride tests and acetylcholine receptor antibodies were negative. Prednisone therapy and intravenous gamma globulin were associated with rapid clinical recovery.Conclusions:Prednisone therapy and intravenous gamma globulin may be helpful in patients with generalized myasthenia gravis complicating HIV infection.

Management of Human Immunodeficiency Virus-Associated Thrombocytopenia with Intravenous Gamma Globulin

1987 ◽  
Vol 9 (4) ◽  
pp. 299-301 ◽  
Author(s):  
Joanne Kurtzberg ◽  
Henry S. Friedman ◽  
Thomas R. Kinney ◽  
Sara Chaffee ◽  
Kimo Stine ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Gamma Globulin ◽  
Immunodeficiency Virus ◽  
Intravenous Gamma Globulin

Distinct light microscopic changes in human immunodeficiency virus-associated nemaline myopathy

Neurology ◽  
1998 ◽  
Vol 50 (2) ◽  
pp. 529-531 ◽  
Author(s):  
D. M. Feinberg ◽  
A. J. Spiro ◽  
K. M. Weidenheim
Keyword(s):  
Human Immunodeficiency Virus ◽  
Nemaline Myopathy ◽  
Immunodeficiency Virus

Chemotherapy is successful in sporadic late onset nemaline myopathy (SLONM) with monoclonal gammopathy

2009 ◽  
Vol 41 (2) ◽  
pp. 286-287 ◽  
Author(s):  
Jan Novy ◽  
Anne Rosselet ◽  
Olivier Spertini ◽  
Johannes Alexander Lobrinus ◽  
Thomas Pabst ◽  
...  
Keyword(s):  
Monoclonal Gammopathy ◽  
Late Onset ◽  
Nemaline Myopathy

Older Children and Adolescents Living With Perinatally Acquired Human Immunodeficiency Virus Infection

PEDIATRICS ◽  
1995 ◽  
Vol 95 (5) ◽  
pp. 657-663
Author(s):  
Samuel Grubman ◽  
Elaine Gross ◽  
Nancy Lerner-Weiss ◽  
Myriam Hernandez ◽  
George D. McSherry ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Hiv Infection ◽  
Children And Adolescents ◽  
Late Onset ◽  
Medical Center ◽  
Symptomatic Disease ◽  
Immunodeficiency Virus ◽  
Perinatally Acquired ◽  
The Mean

Objective. To describe the clinical, immunologic, and psychosocial characteristics of children living with perinatally-acquired human immunodeficiency virus (HIV) infection beyond the age of 9 years. Methods. This is a descriptive cohort study of 42 surviving perinatally infected children older than 9 years followed at the Children's Hospital Acquired Immunodeficiency Syndrome (AIDS) Program (part of a university-based inner city medical center) as of June 1993. The study is based on medical record data of clinical, immunologic, and psychosocial parameters. Results. The cohort includes 20 boys and 22 girls with a mean age of 136 months. The mean age at diagnosis of HIV infection was 88 months, and 59.5% were asymptomatic at the time of diagnosis. Currently, after a mean follow-up period of 48 months from diagnosis, 23.8% remain asymptomatic, 19.1% have non-AIDS-defining HIV-related symptoms, and 57.1% have AIDS; 85.7% of the cohort did not develop HIV-related symptoms until after 48 months of age (late-onset prolonged survivors). There was an average annual decline of 71.4 CD4+ cells/µL in the cohort from the ages of 7 to 16 years, and 21.4% have a current CD4+ lymphocyte count of greater than 500 cells/µL, 28.6% between 200 and 500 cells/µL, and 50% less than 200 cells/µL; 76% are orphaned as a result of maternal death, with the majority of the cohort (60%) cared for by extended family members. Disclosure of diagnosis has occurred in 57.1%. The vast majority of the cohort (76%) are attending regular school, with the remainder in special education. Conclusions. Although close to one quarter of the children and adolescents ages 9 to 16 years living with perinatally acquired HIV infection described in this cohort remain asymptomatic and have a relatively intact immune system, the remainder are living with significant HIV-related symptoms, many of which are chronic in nature and have an impact on daily living. The children in this cohort had both significant immunologic deterioration and symptomatic disease progression during the mean follow-up period of 48 months from the time of diagnosis with HIV infection.

Sign in / Sign up

Export Citation Format

Share Document